Cellecta, Inc. was founded in April 2006 by one of the chief scientists from Clontech Laboratories. The company was borne out of the need for higher quality, more advanced shRNA, and other lentiviral libraries. Our goal is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.

We offer a variety of products and custom services that include:

CRISPR/RNAi Genetic Screens, Libraries, and Constructs

DriverMap™ Targeted RNA Expression Profiling

CloneTracker™ Barcode Libraries.